JP2021520800A5 - - Google Patents
Info
- Publication number
- JP2021520800A5 JP2021520800A5 JP2020555222A JP2020555222A JP2021520800A5 JP 2021520800 A5 JP2021520800 A5 JP 2021520800A5 JP 2020555222 A JP2020555222 A JP 2020555222A JP 2020555222 A JP2020555222 A JP 2020555222A JP 2021520800 A5 JP2021520800 A5 JP 2021520800A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- human
- polynucleotide
- target sequence
- cleavage site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023104634A JP2023138965A (ja) | 2018-04-12 | 2023-06-27 | ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ |
| JP2025083934A JP2025131624A (ja) | 2018-04-12 | 2025-05-20 | ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656809P | 2018-04-12 | 2018-04-12 | |
| US62/656,809 | 2018-04-12 | ||
| PCT/US2019/027019 WO2019200122A1 (en) | 2018-04-12 | 2019-04-11 | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023104634A Division JP2023138965A (ja) | 2018-04-12 | 2023-06-27 | ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021520800A JP2021520800A (ja) | 2021-08-26 |
| JP2021520800A5 true JP2021520800A5 (enExample) | 2023-03-07 |
| JP7304888B2 JP7304888B2 (ja) | 2023-07-07 |
Family
ID=66380156
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555222A Active JP7304888B2 (ja) | 2018-04-12 | 2019-04-11 | ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ |
| JP2023104634A Pending JP2023138965A (ja) | 2018-04-12 | 2023-06-27 | ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ |
| JP2025083934A Pending JP2025131624A (ja) | 2018-04-12 | 2025-05-20 | ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023104634A Pending JP2023138965A (ja) | 2018-04-12 | 2023-06-27 | ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ |
| JP2025083934A Pending JP2025131624A (ja) | 2018-04-12 | 2025-05-20 | ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11786554B2 (enExample) |
| EP (2) | EP4275697A3 (enExample) |
| JP (3) | JP7304888B2 (enExample) |
| KR (2) | KR102617818B1 (enExample) |
| CN (2) | CN120249250A (enExample) |
| AU (3) | AU2019252527B2 (enExample) |
| CA (1) | CA3095795A1 (enExample) |
| ES (1) | ES2955408T3 (enExample) |
| IL (4) | IL277883B2 (enExample) |
| MX (2) | MX2020010795A (enExample) |
| WO (1) | WO2019200122A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2768984T3 (es) | 2015-10-05 | 2020-06-24 | Prec Biosciences Inc | Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas |
| ES2803728T3 (es) | 2015-10-05 | 2021-01-29 | Prec Biosciences Inc | Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado |
| AU2017248259A1 (en) * | 2016-04-07 | 2018-10-25 | Bluebird Bio, Inc. | Chimeric antigen receptor T cell compositions |
| EP4775669A2 (en) | 2017-06-30 | 2026-07-15 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| KR102617818B1 (ko) * | 2018-04-12 | 2023-12-27 | 프리시젼 바이오사이언시스 인코포레이티드 | 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제 |
| CN114026228A (zh) | 2019-05-07 | 2022-02-08 | 精密生物科学公司 | 用于识别序列的工程化大范围核酸酶的优化 |
| US20220273715A1 (en) | 2019-07-25 | 2022-09-01 | Precision Biosciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
| WO2021231259A1 (en) | 2020-05-11 | 2021-11-18 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| WO2022165111A1 (en) | 2021-01-28 | 2022-08-04 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| WO2023133525A1 (en) | 2022-01-07 | 2023-07-13 | Precision Biosciences, Inc. | Optimized polynucleotides for protein expression |
| IL321936A (en) | 2023-01-05 | 2025-09-01 | Prec Biosciences Inc | Optimized engineered meganucleases with specificity for the human T-cell receptor alpha constant region gene |
| WO2026083329A1 (en) | 2024-10-18 | 2026-04-23 | Precision Biosciences, Inc. | Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof |
| WO2026083328A1 (en) | 2024-10-18 | 2026-04-23 | Precision Biosciences, Inc. | Base editing nucleotide sequences using homology directed repair |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
| US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| DK3246403T3 (da) | 2005-10-18 | 2020-10-26 | Prec Biosciences | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
| WO2009001159A1 (en) | 2007-06-25 | 2008-12-31 | Cellectis | Method for enhancing the cleavage activity of i-crei derived meganucleases |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| ES2422291T3 (es) | 2007-10-31 | 2013-09-10 | Prec Biosciences Inc | Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas |
| EP2329017A2 (en) | 2008-08-04 | 2011-06-08 | Cellectis | Novel method to generate meganucleases with altered characteristics |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| CA2805442C (en) | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
| EP3683319A1 (en) | 2011-06-01 | 2020-07-22 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| KR20140019635A (ko) | 2012-08-06 | 2014-02-17 | 엘지이노텍 주식회사 | 발광 소자 및 발광 소자 패키지 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| AU2014235968B2 (en) | 2013-03-21 | 2018-05-24 | Ospedale San Raffaele Srl | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| JP6608807B2 (ja) | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
| CA2913872C (en) | 2013-05-31 | 2022-01-18 | Cellectis | A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof |
| CA2913871C (en) | 2013-05-31 | 2021-07-13 | Cellectis | A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof |
| EP3058072B1 (en) | 2013-10-17 | 2021-05-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| DK3105317T3 (en) | 2014-02-14 | 2019-01-14 | Cellectis | Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells |
| RU2752933C2 (ru) | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| AU2015229299A1 (en) | 2014-03-12 | 2016-09-22 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
| WO2015167766A1 (en) | 2014-04-29 | 2015-11-05 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies |
| DK3152312T3 (da) | 2014-06-06 | 2020-04-06 | Regeneron Pharma | Fremgangsmåder og sammensætninger til modifikation af et mållocus |
| US20160081314A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
| KR102546296B1 (ko) | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
| BR112017020750A2 (en) | 2015-03-27 | 2018-06-26 | President And Fellows Of Harvard College | modified t-cells and methods of producing and using them |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| CA2991301A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| EP4339287A3 (en) | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| ES2803728T3 (es) | 2015-10-05 | 2021-01-29 | Prec Biosciences Inc | Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado |
| ES2768984T3 (es) | 2015-10-05 | 2020-06-24 | Prec Biosciences Inc | Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas |
| WO2017070429A1 (en) * | 2015-10-22 | 2017-04-27 | Regents Of The University Of Minnesota | Methods involving editing polynucleotides that encode t cell receptor |
| EP3393500B1 (en) | 2015-12-21 | 2021-10-13 | Duke University | Polymer conjugates having reduced antigenicity |
| US20190017075A1 (en) | 2015-12-23 | 2019-01-17 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| US20190241910A1 (en) | 2016-03-11 | 2019-08-08 | Bluebird Bio, Inc. | Genome edited immune effector cells |
| KR102614675B1 (ko) | 2016-04-15 | 2023-12-19 | 메모리얼 슬로안 케터링 캔서 센터 | 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법 |
| EP4775669A2 (en) | 2017-06-30 | 2026-07-15 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| KR102617818B1 (ko) * | 2018-04-12 | 2023-12-27 | 프리시젼 바이오사이언시스 인코포레이티드 | 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제 |
-
2019
- 2019-04-11 KR KR1020207032271A patent/KR102617818B1/ko active Active
- 2019-04-11 EP EP23181141.5A patent/EP4275697A3/en active Pending
- 2019-04-11 MX MX2020010795A patent/MX2020010795A/es unknown
- 2019-04-11 CN CN202510427175.9A patent/CN120249250A/zh active Pending
- 2019-04-11 IL IL277883A patent/IL277883B2/en unknown
- 2019-04-11 US US17/046,761 patent/US11786554B2/en active Active
- 2019-04-11 IL IL304025A patent/IL304025A/en unknown
- 2019-04-11 EP EP19721447.1A patent/EP3774871B1/en active Active
- 2019-04-11 CA CA3095795A patent/CA3095795A1/en active Pending
- 2019-04-11 JP JP2020555222A patent/JP7304888B2/ja active Active
- 2019-04-11 AU AU2019252527A patent/AU2019252527B2/en active Active
- 2019-04-11 IL IL317539A patent/IL317539A/en unknown
- 2019-04-11 KR KR1020237044104A patent/KR20240005139A/ko active Pending
- 2019-04-11 IL IL325516A patent/IL325516A/en unknown
- 2019-04-11 WO PCT/US2019/027019 patent/WO2019200122A1/en not_active Ceased
- 2019-04-11 CN CN201980037689.6A patent/CN112218889B/zh active Active
- 2019-04-11 ES ES19721447T patent/ES2955408T3/es active Active
-
2020
- 2020-10-12 MX MX2023006456A patent/MX2023006456A/es unknown
-
2023
- 2023-06-27 JP JP2023104634A patent/JP2023138965A/ja active Pending
- 2023-09-05 US US18/461,190 patent/US20240000845A1/en not_active Abandoned
-
2024
- 2024-05-15 AU AU2024203244A patent/AU2024203244A1/en not_active Abandoned
-
2025
- 2025-01-17 US US19/029,983 patent/US20250333468A1/en active Pending
- 2025-05-20 JP JP2025083934A patent/JP2025131624A/ja active Pending
-
2026
- 2026-06-26 AU AU2026205012A patent/AU2026205012A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018538000A5 (enExample) | ||
| US10858662B2 (en) | Genome editing with split Cas9 expressed from two vectors | |
| IL277883B2 (en) | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene | |
| Yao et al. | Tild-CRISPR allows for efficient and precise gene knockin in mouse and human cells | |
| JP2018536390A5 (enExample) | ||
| KR102243243B1 (ko) | 신규한 cho 통합 부위 및 이의 용도 | |
| JP6482757B2 (ja) | トランスジェニック動物および使用方法 | |
| IL295858B1 (en) | gRNA molecules including TRACR and crRNA, compositions containing them and their use | |
| AU2017337147A1 (en) | Modified stem cell memory T cells, methods of making and methods of using same | |
| MX2023012498A (es) | Metodos escalables para producir vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspension libre de suero adecuado para su uso clinico. | |
| CN108884475A (zh) | 转基因的位点特异性整合 | |
| JP2018530336A5 (enExample) | ||
| JP2008545406A5 (enExample) | ||
| CN104379753A (zh) | 位点特异性整合 | |
| RU2012130149A (ru) | Векторная система на основе aslv | |
| RU2019139045A (ru) | Способы и композиции для модификации гена регулятора трансмембранной проводимости при кистозном фиброзе (cftr) | |
| RU2017121232A (ru) | Плазмиды и способ получения вирусных частиц | |
| CN110177878B (zh) | 转基因动物和生物生产方法 | |
| CN103805606B (zh) | 一对特异识别绵羊DKK1基因的sgRNA及其编码DNA和应用 | |
| CN106086070B (zh) | 一种ProtoRAG转座子系统及其用途 | |
| CN103421793B (zh) | 猪肝脏特异性表达基因ttr启动子的克隆及应用 | |
| WO2023235879A1 (en) | Methods of genome editing oocytes | |
| JP4665190B2 (ja) | 遺伝子の転写調節方法 | |
| CN114908122B (zh) | 一种用于表达外源蛋白的新型流感病毒载体及其构建方法 | |
| CN104561005B (zh) | 一种用于对虾细胞的启动子 |